STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

Their data suggests that tweaking the expression of FDX2 could make up for the loss of frataxin, the protein tied to FA's development.